Lanoconazole
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598304

CAS#: 101530-10-3

Description: Lanoconazole is a topical antifungal agent.


Price and Availability

Size
Price

25mg
USD 340
Size
Price

Size
Price

Lanoconazole purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 598304
Name: Lanoconazole
CAS#: 101530-10-3
Chemical Formula: C14H10ClN3S2
Exact Mass: 319.0005
Molecular Weight: 319.82
Elemental Analysis: C, 52.58; H, 3.15; Cl, 11.08; N, 13.14; S, 20.05


Synonym: Lanoconazole; Astat; NND-318; TJN-318;

IUPAC/Chemical Name: (E)-2-(4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene)-2-(1H-imidazol-1-yl)acetonitrile

InChi Key: ZRTQSJFIDWNVJW-WYMLVPIESA-N

InChi Code: InChI=1S/C14H10ClN3S2/c15-11-4-2-1-3-10(11)13-8-19-14(20-13)12(7-16)18-6-5-17-9-18/h1-6,9,13H,8H2/b14-12+

SMILES Code: N#C/C(N1C=CN=C1)=C2SCC(C3=CC=CC=C3Cl)S/2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Uratsuji H, Nakamura A, Yamada Y, Hashimoto K, Matsumoto T, Ikeda F, Ishii R. Anti-inflammatory activity of lanoconazole, a topical antifungal agent. Mycoses. 2015 Apr;58(4):197-202. doi: 10.1111/myc.12297. Epub 2015 Feb 10. PubMed PMID: 25675966.

2: Abastabar M, Rahimi N, Meis JF, Aslani N, Khodavaisy S, Nabili M, Rezaei-Matehkolaei A, Makimura K, Badali H. Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6916-6919. doi: 10.1128/AAC.01193-16. Print 2016 Nov. PubMed PMID: 27572389; PubMed Central PMCID: PMC5075107.

3: Ghannoum MA, Long L, Kim HG, Cirino AJ, Miller AR, Mallefet P. Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model. Med Mycol. 2010 May;48(3):491-7. doi: 10.3109/13693780903373811. PubMed PMID: 20370362.

4: Ghannoum MA, Welshenbaugh A, Imamura Y, Isham N, Mallefet P, Yamaguchi H. Comparison of the in vitro activity of terbinafine and lanoconazole against dermatophytes. Mycoses. 2010 Jul;53(4):311-3. doi: 10.1111/j.1439-0507.2009.01723.x. Epub 2009 May 5. PubMed PMID: 19422522.

5: Niwano Y, Koga H, Kanai K, Hamaguchi H, Yamaguchi H. Wound healing effect of the new imidazole antimycotic lanoconazole in rats. Arzneimittelforschung. 1996 Feb;46(2):218-23. PubMed PMID: 8720319.

6: Niwano Y, Matsui M, Tabuchi T, Kanai K, Hamaguchi H, Miyazaki T, Uchida K, Yamaguchi H. Studies on the antifungal activity of the new imidazole antimycotic lanoconazole in infected sites. Distribution in the skin and in vitro activity in the presence of stratum corneum. Arzneimittelforschung. 1997 Sep;47(9):1056-60. PubMed PMID: 9342423.

7: Baghi N, Shokohi T, Badali H, Makimura K, Rezaei-Matehkolaei A, Abdollahi M, Didehdar M, Haghani I, Abastabar M. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. Med Mycol. 2016 Oct 1;54(7):757-63. doi: 10.1093/mmy/myw016. Epub 2016 Apr 26. PubMed PMID: 27118804.

8: Furukawa K, Sasaki H, Pollard RB, Suzuki F. Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans. J Antimicrob Chemother. 2000 Sep;46(3):443-50. PubMed PMID: 10980172.

9: Kumar AP, Ganesh VR, Rao DV, Anil C, Hariharakrishnan VS. Separation and quantitation of Z-isomer in lanoconazole by normal phase HPLC. J Pharm Biomed Anal. 2009 Oct 15;50(3):535-7. doi: 10.1016/j.jpba.2009.05.004. Epub 2009 May 15. PubMed PMID: 19487097.

10: Niwano Y, Tabuchi T, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H. [Therapeutic efficacy of lanoconazole ointment in guinea pig model of tinea corporis, a comparative study with ointment and cream preparations]. Jpn J Antibiot. 1995 Jan;48(1):150-4. Japanese. PubMed PMID: 7699840.

11: Tanaka N, Kawada A, Hiruma M, Tajima S, Ishibashi A. Contact dermatitis from lanoconazole. Contact Dermatitis. 1996 Oct;35(4):256-7. PubMed PMID: 8957656.

12: Nishiyama Y, Nakaoka C, Hiratani T, Abe S, Uchida K, Yamaguchi H. Synergy of lysozyme and lanoconazole on the morphology of Candida albicans. J Electron Microsc (Tokyo). 2001;50(1):41-9. PubMed PMID: 11291959.

13: Umebayashi Y, Ito S. Allergic contact dermatitis due to both lanoconazole and neticonazole ointments. Contact Dermatitis. 2001 Jan;44(1):48-9. PubMed PMID: 11156023.

14: Nakano R, Miyoshi H, Kanzaki T. Allergic contact dermatitis from lanoconazole. Contact Dermatitis. 1996 Jul;35(1):63. PubMed PMID: 8896974.

15: Tanuma H, Tanuma M, Abe M, Kume H. Usefulness of lanoconazole (Astat) cream in the treatment of hyperkeratotic type tinea pedis. Comparative study of monotherapy and combination therapy with 10% urea ointment (Pastaron). Mycoses. 2001;44(5):181-90. PubMed PMID: 11486456.

16: Niwano Y, Tabuchi T, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H. [Therapeutic efficacy of lanoconazole ointment in guinea pig model of tinea pedis, in comparison with that of cream preparations]. Jpn J Antibiot. 1994 Sep;47(9):1192-5. Japanese. PubMed PMID: 7990259.

17: Niwano Y, Seo A, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H. Therapeutic efficacy of lanoconazole, a new imidazole antimycotic agent, for experimental cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother. 1994 Sep;38(9):2204-6. PubMed PMID: 7811048; PubMed Central PMCID: PMC284713.

18: Niwano Y, Ohmi T, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H. [In vitro antifungal activities of lanoconazole against stock cultures and clinical isolates of Candida albicans]. Jpn J Antibiot. 1995 Jan;48(1):140-5. Japanese. PubMed PMID: 7699837.

19: Taniguchi S, Kono T. Allergic contact dermatitis due to lanoconazole with no cross-reactivity to other imidazoles. Dermatology. 1998;196(3):366. PubMed PMID: 9621155.

20: Mitsuya M, Wada K, Ishibashi H, Tansho S, Abe S, Yamaguchi H. [Suppressive effects of lanoconazole on arthus phenomenon in vivo and on production and functions of TNF in vitro]. Nihon Ishinkin Gakkai Zasshi. 2000;41(2):97-102. Japanese. PubMed PMID: 10777820.